385 related articles for article (PubMed ID: 31544891)
1. ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates.
Mou S; Huang Y; Rosenbaum AI
Antibodies (Basel); 2018 Nov; 7(4):. PubMed ID: 31544891
[TBL] [Abstract][Full Text] [Related]
2. Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2.
Faria M; Peay M; Lam B; Ma E; Yuan M; Waldron M; Mylott WR; Liang M; Rosenbaum AI
Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544817
[TBL] [Abstract][Full Text] [Related]
3. Current Analytical Strategies for Antibody-Drug Conjugates in Biomatrices.
Qin Q; Gong L
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234836
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM.
Huang Y; Mou S; Wang Y; Mu R; Liang M; Rosenbaum AI
Anal Chem; 2021 Apr; 93(15):6135-6144. PubMed ID: 33835773
[TBL] [Abstract][Full Text] [Related]
5. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
6. Bioanalytical Assays for Pharmacokinetic and Biodistribution Study of Antibody-Drug Conjugates.
Yin L; Xu A; Zhao Y; Gu J
Drug Metab Dispos; 2023 Oct; 51(10):1324-1331. PubMed ID: 37290939
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
Lin K; Tibbitts J; Shen BQ
Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
[TBL] [Abstract][Full Text] [Related]
8. Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.
Sauerborn M; van Dongen W
BioDrugs; 2014 Aug; 28(4):383-91. PubMed ID: 24842227
[TBL] [Abstract][Full Text] [Related]
9. [Bioanalysis in the development of antibody-drug conjugates].
Li XL; Chen XY; Zhong DF
Yao Xue Xue Bao; 2016 Apr; 51(4):517-28. PubMed ID: 29859519
[TBL] [Abstract][Full Text] [Related]
10. Calculated conjugated payload from immunoassay and LC-MS intact protein analysis measurements of antibody-drug conjugate.
Rago B; Clark T; King L; Zhang J; Tumey LN; Li F; Barletta F; Wei C; Leal M; Hansel S; Han X
Bioanalysis; 2016 Nov; 8(21):2205-2217. PubMed ID: 27682846
[TBL] [Abstract][Full Text] [Related]
11. Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.
Saad OM; Shen BQ; Xu K; Khojasteh SC; Girish S; Kaur S
Bioanalysis; 2015; 7(13):1583-604. PubMed ID: 26226309
[TBL] [Abstract][Full Text] [Related]
12. Bioanalytical methods for therapeutic monoclonal antibodies and antibody-drug conjugates: A review of recent advances and future perspectives.
Todoroki K; Mizuno H; Sugiyama E; Toyo'oka T
J Pharm Biomed Anal; 2020 Feb; 179():112991. PubMed ID: 31761377
[TBL] [Abstract][Full Text] [Related]
13. Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte.
Hyung SJ; Li D; Koppada N; Kaur S; Saad OM
Anal Bioanal Chem; 2019 May; 411(12):2587-2596. PubMed ID: 30828756
[TBL] [Abstract][Full Text] [Related]
14. Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-Generation Antibody Drug Conjugates.
Lee MV; Kaur S; Saad OM
Anal Chem; 2020 Sep; 92(18):12168-12175. PubMed ID: 32786429
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Pharmacokinetic Bioanalysis of Antibody-drug Conjugates using Hybrid Immunoaffinity Capture and Microflow LC-MS/MS.
Suh MJ; Powers JB; Daniels CM; Wu Y
AAPS J; 2023 Jun; 25(4):68. PubMed ID: 37386323
[TBL] [Abstract][Full Text] [Related]
16. LC/MS/MS Bioanalysis of Protein-Drug Conjugates-The Importance of Incorporating Succinimide Hydrolysis Products.
Shi C; Goldberg S; Lin T; Dudkin V; Widdison W; Harris L; Wilhelm S; Jmeian Y; Davis D; O'Neil K; Weng N; Jian W
Anal Chem; 2018 Apr; 90(8):5314-5321. PubMed ID: 29589741
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic considerations for antibody drug conjugates.
Lin K; Tibbitts J
Pharm Res; 2012 Sep; 29(9):2354-66. PubMed ID: 22740180
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
19. ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs).
Beaumont K; Pike A; Davies M; Savoca A; Vasalou C; Harlfinger S; Ramsden D; Ferguson D; Hariparsad N; Jones O; McGinnity D
Xenobiotica; 2022 Aug; 52(8):770-785. PubMed ID: 36314242
[TBL] [Abstract][Full Text] [Related]
20. Determination of ADC Concentration by Ligand-Binding Assays.
Chang HP; Shah DK
Methods Mol Biol; 2020; 2078():361-369. PubMed ID: 31643071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
